Skip to main content

Holiday schedule

Our Patient Service Centers will be closed on Wednesday, December 25, 2024 in observance of Christmas and Wednesday, January 1, 2025 in observance of New Year's Day. Have a healthy, happy holiday.

Hide
Quest Diagnostics

Gastrointestinal & digestive diseases

Breaking down the barriers to gastrointestinal testing

Despite the importance of early detection for colon cancer, inflammatory bowel disease, and other gastrointestinal conditions, many patients are resistant to testing due to concerns with the preparation and procedures involved with these vital screenings.

Recognizing these barriers, Quest Diagnostics offers an extensive menu of minimal-prep testing that preempts patient hesitation while delivering reliable results. These patient-friendly options—combined with the medical expertise of our infectious disease and gastrointestinal pathology teams and world-class turnaround times—make for a winning combination.

Keeping current with colorectal screening guidelines

The prevalence of digestive diseases has a significant impact in the United States, with more than 60 million Americans diagnosed each year. These conditions lead to more hospitalizations than any other disease state and represent the third-highest economic loss of all illnesses. Given the complexity of digestive diseases and the subtle presentation of symptoms, early and accurate detection is essential.1

When the American Cancer Society lowered its colorectal cancer screening age guideline from 50 to 45 for average-risk patients, an estimated 21 million people in the U.S. became newly eligible for screenings. Options include visual exams, such as a colonoscopy, and stool-based tests. Stool-based screenings are required more frequently than visual exams and should always be followed by a colonoscopy if results are abnormal. 
 

Learn more about Quest colorectal screening at QuestInSureONE.com

A comprehensive range of testing

Guidelines-based colorectal cancer testing

When colorectal cancer is caught in early stages, patients experience a 5-year survival rate exceeding 90%.2 And yet, more than 6 in 10 colorectal cancer patients receive their diagnosis after the cancer has already advanced. Once colorectal cancer spreads to distant organs, the 5-year survival rate drops to just 14%.2

These statistics emphasize the need for more screening, as well as the need to match diagnosed patients with highly targeted therapies. With noninvasive at-home kits and next-generation cancer genetic sequencing, Quest’s test menu supports providers in both objectives.

Colorectal cancer tests:

Comprehensive screening for celiac disease

The primary care community plays a pivotal role in identifying individuals at high risk for celiac disease (CD), performing serological testing as one of the first steps to diagnosis, and monitoring over time to detect associated conditions and nutritional deficiencies. Quest offers 3 serologic testing panels and genetic screenings so you can provide patients with fast, reliable insights.

Celiac disease tests:

Differential diagnosis of inflammatory bowel disease

Inflammatory bowel disease (IBD) involves chronic inflammation along the digestive tract at various sites, and includes Crohn disease (CD) and ulcerative colitis (UC). Because CD and UC manifest differently in digestive tissue and have different prognoses and treatments, differentiating between them is paramount. And yet, up to 15% of patients with IBD have cases that cannot be distinguished by clinical, radiographic, endoscopic, or histologic methods.3

Quest offers a range of stool and serum based assays that help rule out other possible conditions, confirm the presence of inflammation, and differentiate between inflammatory bowel syndrome (IBS) and IBD. Additionally, lab testing can help detect active versus remittant disease and predict relapse in patients with IBD.

Inflammatory bowel disease tests:

Specific diagnosis for symptoms of infectious diarrhea

When a patient presents with diarrhea, it’s important to determine whether the symptoms are caused by a bacteria, virus, or parasite in order to properly treat the infection. For some pathogens, an organism-specific diagnosis is required.4

Our broad infectious diarrhea testing menu can help you arrive at a differential diagnosis efficiently, so effective treatment can begin sooner.

Learn more about our infectious diarrhea tests


The power of Quest

Comprehensive test menu

Our comprehensive testing menu includes screens for a range of gastrointestinal conditions including IBD, gluten and food sensitivity, peptic ulcer disease, digestive disorders, and colorectal cancer. Many options are noninvasive, with no dietary or medicine restrictions, to help preempt patient resistance and enable a more relaxed and comfortable experience.

Medical experts

Whether you need a professional consultation about assay selection or support through rare or complex testing, our experienced gastrointestinal pathology team is here for you. With board-certified doctors, scientists, specialists, and technicians, we are always ready to provide swift guidance and materials for the most nuanced of diagnoses.

Easy-to-use patient tools

Empower your patients to take an active role in their care through our extensive collection of tools and materials. With an interactive content library, free lab and appointment reminders, and the MyQuest™ app, it’s never been easier for patients to keep their healthcare on track.  

Quanum® electronic health record

Spend more time with patients and less time clicking with our cloud-based EHR for dynamic and secure access to patient information anytime, anywhere. With this powerful and fully mobile solution, providers can easily manage labs, ePrescribe, submit prior authorizations, and do so much more—right from the patient record.

References

  1. GI Alliance. Digestive disease continues to rise among Americans. February 23, 2021. Accessed August 18, 2021. https://gialliance.com/digestive-disease-continues-to-rise-among-americans/
  2. NCI Surveillance, Epidemiology, and End Results Program (SEER). Cancer stat facts: colorectal cancer. Survival statistics: 5-year relative survival. Accessed July 31, 2020. https://seer.cancer.gov/statfacts/html/colorect.html
  3. Savige J, Dimech W, Fritzler M, et al. Addendum to the International Consensus Statement on testing and reporting of antineutrophil cytoplasmic antibodies. Quality control guidelines, comments, and recommendations for testing in other autoimmune diseases. Am J Clin Pathol. 2003;120(3):312-318. doi:10.1309/WAEP-ADW0-K4LP-UHFN
  4. Shane L, Mody RK, Crump JA, et al. 2017 Infectious Diseases Society of America clinical practice guidelines for the diagnosis and management of infectious diarrhea. Clin Infect Dis. 2017;65(12):1963-1973. doi:10.1093/cid/cix959

During the COVID-19 health crisis, fast action and trusted information matter more than ever.

Find out what's happening

Learn More

About our tests

Resources

Inflammatory bowel disease: Laboratory support for diagnosis and management

Celiac Disease Comprehensive Panel with Gliadin Antibody (IgG)

ACG clinical guideline: Treatment of Helicobacter pylori infection

2017 Infectious Diseases Society of America clinical practice guidelines for the diagnosis and management of infectious diarrhea

InSure® ONE™: Helping your patients with easy-to-use, in-home colorectal cancer screening

Our company

Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA-certified laboratories that provide HIPAA-covered services.  Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA-covered services. 

 

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2024 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only.